<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00762671</url>
  </required_header>
  <id_info>
    <org_study_id>1999-P-003331Ebselen</org_study_id>
    <nct_id>NCT00762671</nct_id>
  </id_info>
  <brief_title>Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus</brief_title>
  <official_title>Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to learn how blood vessel function is altered by diabetes. We are&#xD;
      studying an investigational drug, Ebselen, to see if it can improve the ability of blood&#xD;
      vessels to relax (widen).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A major cause of death and disability in patients with diabetes mellitus is atherosclerosis.&#xD;
      Endothelial dysfunction is an important, if not primary, factor in atherogenesis. Nitric&#xD;
      oxide is an important substance made and released by the endothelium. Many prior studies in&#xD;
      animals and humans have shown that the ability of the blood vessel to dilate is impaired in&#xD;
      diabetes. This process of vasodilation is mediated by a substance, nitric oxide, which is&#xD;
      thought to be highly susceptible to destruction by oxidant molecules. In previous studies, we&#xD;
      found that acute administration of the antioxidant, vitamin C, improves endothelium-dependent&#xD;
      vasodilation in blood vessels of patients with type 1 and type 2 diabetes. This suggests that&#xD;
      by scavenging oxidants, such as superoxide, vitamin C may reduce the destruction of nitric&#xD;
      oxide and thereby preserve endothelial function. Additional mechanisms, including activation&#xD;
      of a substance called protein kinase C, and oxidant stress from excess soluble peroxides may&#xD;
      be present in diabetes and interact with oxidant stress to cause endothelial dysfunction in&#xD;
      patients with diabetes. Accordingly, we would like to study both of these mechanisms to&#xD;
      determine their contribution to endothelial dysfunction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1999</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelium-dependent and endothelium-independent vasodilation of peripheral resistance and conduit vessels will be studied in diabetic (type 1 and 2) and healthy subjects two weeks following randomization to the ebselen or placebo.</measure>
    <time_frame>one testing visit every 4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ebselen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ebselen</intervention_name>
    <description>150 mg BID for 2 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 1 po BID for 2 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with diabetes mellitus will be eligible if they are receiving dietary&#xD;
             treatment for hyperglycemia, sulfonylureas, metformin or insulin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any diabetic subject with a HgbA1C level of &lt;7% or &gt;11%&#xD;
&#xD;
          -  Evidence of atherosclerosis&#xD;
&#xD;
          -  symptoms of angina&#xD;
&#xD;
          -  symptoms of claudication&#xD;
&#xD;
          -  symptoms of cerebrovascular ischemia&#xD;
&#xD;
          -  findings of arterial occlusive disease, as would be suggested by decreased pulses,&#xD;
             asymmetric blood pressure, bruits or reduced limb pressure measurements&#xD;
&#xD;
          -  hypertension defined as a systolic blood pressure &gt; = 150 mmHg and a diastolic blood&#xD;
             pressure &gt;= 95 mmHg; (allowable blood pressure medications for diabetic subjects&#xD;
             include calcium channel blockers, alpha and beta adrenergic blockers, and diuretics)&#xD;
&#xD;
          -  hypercholesterolemia, defined as total cholesterol levels greater than 75th percentile&#xD;
             for age and sex and LDL cholesterol levels &gt;130mg/dL.&#xD;
&#xD;
          -  renal insufficiency (serum creatinine &gt;1.5 mg/dL for men; &gt;1.2 mg/dL for women)&#xD;
&#xD;
          -  hepatic dysfunction defined as liver enzyme abnormalities &gt; two times the upper limit&#xD;
             of normal&#xD;
&#xD;
          -  chronic pulmonary disease&#xD;
&#xD;
          -  congestive heart failure&#xD;
&#xD;
          -  pregnancy (or subjects planning to become pregnant);&#xD;
&#xD;
          -  history of cigarette smoking within the last five years;&#xD;
&#xD;
          -  history of clinically significant coronary artery or cerebrovascular disease (defined&#xD;
             as MI or stroke within 6 months, or presence of unstable angina)&#xD;
&#xD;
               -  use of any, vasoactive, cardioactive, or non-steroidal anti-inflammatory&#xD;
                  medications within 24 hours of vascular testing visits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark A Creager, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hosptial</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hosptial</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>September 26, 2008</study_first_submitted>
  <study_first_submitted_qc>September 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2008</study_first_posted>
  <last_update_submitted>September 29, 2008</last_update_submitted>
  <last_update_submitted_qc>September 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2008</last_update_posted>
  <responsible_party>
    <name_title>Mark A. Creager, MD</name_title>
    <organization>Brigham and Women's Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ebselen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

